Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846742 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
A Phase 2 study of Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 6
- Study locations
NCT00846742 is a Phase 2 study of Hodgkin Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 88 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (47% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT00846742, a Phase 2 study of Hodgkin Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Stanford V Chemotherapy
Study Locations (6)
California
- Packard Children's Hospital, Stanford University - Palo Alto
- Rady Children's Hospital- San Diego - San Diego
Illinois
- Children's Hospital of Illinois at OSF St. Francis Medical Center - Peoria
Maine
- Maine Children's Cancer Program (MCCP) - Scarborough
Massachusetts
- Dana-Farber Harvard Cancer Center - Boston
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-06-05 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846742
The ClinicalTrials.gov registry entry for NCT00846742 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (47% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT00846742 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Maine.
Frequently Asked Questions
What is clinical trial NCT00846742 about?
NCT00846742 is a clinical study titled "Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma". This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, b...
What is the current status of trial NCT00846742?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2009-06-05. Estimated completion is 2028-10.
What conditions does trial NCT00846742 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT00846742?
The interventions under investigation include: Radiation Therapy (RADIATION), Stanford V Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00846742?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00846742 being conducted?
This trial has 6 study locations across California, Illinois, Maine, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.